In July 2013, Kanebo Cosmetics, a subsidiary of Kao Corporation, voluntarily recalled 54 skin-whitening products across Asia after consumers reported persistent white blotches — leukoderma — that did not fade after they stopped using the products. The cause was rhododenol (4HPB), a proprietary brightening ingredient Kanebo had developed and used across eight sub-brands.
Kanebo had shipped 4.36 million of the affected products in Japan alone and distributed 370,000 overseas. By early 2014, the company had confirmed 19,603 cases of vitiligo-like symptoms and reached 16,856 settlement agreements with affected consumers. Kao booked ¥11.3 billion in recall-related costs and losses, and Kanebo's operating profit fell by an estimated ¥6 billion.
The recall spanned Japan, Hong Kong, South Korea, Taiwan, Thailand, Singapore, Malaysia, Indonesia, Myanmar, the Philippines and Vietnam. In Taiwan, Kanebo's largest overseas market for the products, the local agent pulled 12 items from department-store shelves. The case became a landmark in cosmetics safety regulation across Asia.
Kanebo recalled 54 products across Asia after rhododenol caused irreversible skin blotches in 19,603 users, costing ¥11.3 billion and years of payouts.
Kanebo rushed a novel active ingredient to market without adequate long-term dermatological testing across diverse skin types.
The company treated early consumer complaints as isolated skin conditions rather than a systemic ingredient problem, delaying the recall by months.
A single proprietary compound was embedded across 54 products and eight sub-brands, so one ingredient failure became a portfolio-wide recall.
Kao's 2006 acquisition of Kanebo had not fully integrated safety-review processes, leaving the subsidiary's product-development pipeline under-supervised.
A novel active ingredient needs long-term safety data before it ships in millions of units. One compound embedded across a product line turns a single failure into a portfolio-wide recall.
Kanebo established a compensation programme that was still paying claims years later. Kao consolidated Kanebo's operations and tightened safety review. The case prompted stricter cosmetics-ingredient regulation in Japan and across Asian markets.
FOLLOW THE EVIDENCE